MOVER · WED OCT 14 2026

Why LQDA rose 45.1% on Oct 14 2026: litigation settlement

LQDA+45.1%on Wed Oct 14 2026

Liquidia Corporation Common Stock was up 45.1% on the day at $38.90, ranked #4 on 25.4× its usual five-minute volume, when TapeRank recorded this spike at 04:02 ET during the pre-market session.

THE DAY ON THE LIST · 1 EVENT

  1. 04:02 ET
    MOVER · PRE-MARKET

    $38.90 · ▲ 45.1% ON THE DAY · 25.4× 5M RVOL · RANK #4

    JUSTIFIEDCONFIDENCE5/5

    LQDA is up 47% to $39.40 after announcing a global settlement that resolves six lawsuits with United Therapeutics and preserves YUTREPIA availability for PAH. The agreement removes major litigation uncertainty despite a $380.7 million net payment obligation and explains the sharp repricing.

    WHYA 47% pre-market move is large, but a definitive settlement resolving six lawsuits and preserving the core product is material enough to support it.
    ANALYZED 04:01 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 04:02 ET
    LAST38.90
    DAY▲ 45.1%
    5 MIN▲ 1.04%
    5M RVOL25.4×
    5M $VOL$563K
    FLOAT*89.5M
    RANK#4
    SESSIONPRE-MARKET
    VWAP39.37
    HOD39.50
    LOD37.67
    OR HIGH—
    OR LOW—
    PREV CLOSE26.81
    PM HIGH39.50
    PM LOW37.67
    GAP▲ 45.43% (indicated)

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

    — MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

THE SESSION

  • 09:30 ETOpened at $35.70, +33.2% on the previous close of $26.81
  • 09:37 ETRegular-session high, $38.64
  • 10:55 ETRegular-session low, $33.12
  • 15:59 ETLast trade of the regular session, $34.00, +26.8% on the previous close of $26.81
  • Volume: 16.5M shares in regular hours, 3.5M before the open

LQDA opened at $35.70 after rising 33.2% from the previous close, then reached $38.64 by 09:37 ET before reversing to a $33.12 low at 10:55 ET and ending at $34.00, still up 26.8% for the session. There were no halts. TapeRank read the move as justified by the company’s global settlement resolving six lawsuits with United Therapeutics and preserving YUTREPIA availability for pulmonary arterial hypertension, despite a $380.7 million net payment obligation; the settlement removed major litigation uncertainty and explained the sharp repricing.

WRITTEN THU OCT 15 2026 18:05 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list